For research use only. Not for therapeutic Use.
Cefaclor（Cat No.:I003978）is a second-generation cephalosporin antibiotic used to treat various bacterial infections, including those affecting the respiratory tract, skin, and urinary tract. It works by inhibiting bacterial cell wall synthesis, which leads to cell lysis and death, and is effective against certain Gram-positive and Gram-negative bacteria. Cefaclor’s oral formulation allows for easy administration, making it a convenient option in outpatient settings. Known for its broader spectrum compared to first-generation cephalosporins, cefaclor is a reliable choice for treating common infections, especially when beta-lactamase resistance is a concern.
| Catalog Number | I003978 |
| CAS Number | 53994-73-3 |
| Synonyms | (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Molecular Formula | C15H14ClN3O4S |
| Purity | ≥95% |
| Target | Antibiotic |
| Solubility | DMSO: ＜ 1 mg/mL, H2O: ＜ 1 mg/mL |
| Storage | Store at -20°C |
| IUPAC Name | (6R,7R)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| InChI | InChI=1S/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1 |
| InChIKey | QYIYFLOTGYLRGG-GPCCPHFNSA-N |
| SMILES | C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)Cl |
| Reference | </br>1:Molecularly imprinted polymers based stir bar sorptive extraction for determination of cefaclor and cefalexin in environmental water. Peng J, Liu D, Shi T, Tian H, Hui X, He H.Anal Bioanal Chem. 2017 May 18. doi: 10.1007/s00216-017-0365-z. [Epub ahead of print] PMID: 28516278 </br>2:Do We Bury Antibacterials When Launching? Cefaclor Example. Tomić Z, Tomas A, Vukmirović S, Mikov M, Horvat O, Tomić N, Sabo A.J Pharm Sci. 2016 Mar;105(3):1295-300. doi: 10.1016/j.xphs.2015.12.003. Epub 2016 Jan 30. PMID: 26886327 </br>3:Cefaclor-Induced Generalized Fixed Drug Eruption. Kim EJ, Kim JE, Ro YS, Ko JY.Ann Dermatol. 2015 Aug;27(4):465-6. doi: 10.5021/ad.2015.27.4.465. Epub 2015 Jul 29. No abstract available. PMID: 26273172 Free PMC Article</br>4:Differentiation of cefaclor and its delta-3 isomer by electrospray mass spectrometry, infrared multiple photon dissociation spectroscopy and theoretical calculations. Qian JQ, Correra TC, Li J, Maître P, Song DQ, Hu CQ.J Mass Spectrom. 2015 Jan;50(1):265-9. doi: 10.1002/jms.3510. No abstract available. PMID: 25601701 </br>5:Immunologic evaluation of immediate hypersensitivity to cefaclor. Yoo HS, Kim SH, Kwon HS, Kim TB, Nam YH, Ye YM, Park HS.Yonsei Med J. 2014 Nov;55(6):1473-83. doi: 10.3349/ymj.2014.55.6.1473. PMID: 25323882 Free PMC Article</br>6:Covalent inhibition of New Delhi metallo-β-lactamase-1 (NDM-1) by cefaclor. Thomas PW, Cammarata M, Brodbelt JS, Fast W.Chembiochem. 2014 Nov 24;15(17):2541-8. doi: 10.1002/cbic.201402268. Epub 2014 Oct 10. PMID: 25302694 </br>7:Analysis of cefaclor in novel chocolate-based camouflage capsules. Vetter F, Pohl J, Pohl B, Bracher F.Pharmazie. 2014 Jun;69(6):455-7. PMID: 24974581 </br>8:Structures of cefradine dihydrate and cefaclor dihydrate from DFT-D calculations. van de Streek J, Rantanen J, Bond AD.Acta Crystallogr C. 2013 Nov;69(Pt 11):1229-33. doi: 10.1107/S0108270113026863. Epub 2013 Oct 19. PMID: 24192164 </br>9:Determination of cefaclor by UPLC-MS-MS for a Chinese pharmacokinetic study. Huang C, Wang W, Miao L.J Chromatogr Sci. 2014 Aug;52(7):636-40. doi: 10.1093/chromsci/bmt092. Epub 2013 Jul 9. PMID: 23839802 </br>10:Development of coated beads for oral controlled delivery of cefaclor: In vitro evaluation. Rasool BK, Fahmy SA.Acta Pharm. 2013 Mar;63(1):31-44. doi: 10.2478/acph-2013-0003. PMID: 23482311 |
